EMA to review ridaforolimus

EMA accepted for review an MAA from Merck & Co. Inc. (NYSE:MRK) for ridaforolimus to treat metastatic sarcomas. The acceptance triggers a $25 million milestone payment to Ariad Pharmaceuticals Inc. (N...